Public biopharmaceutical companies have had few problems raising significant cash in 2018, but Proteostasis Therapeutics Inc. withdrew a planned offering of 9m shares on March 20 after an investor with a short position in Proteostasis stock launched an attack on the company's credibility.
Cambridge, Mass.-based Proteostasis announced its proposed offering on March 19 when its stock closed at $6.99 per share, which was...






